000 04347naa a22005777i 4500
001 UMUN-OA-20261005-MLS-059
003 local
005 20261005174906.0
006 m o d
007 cr||||||||||||
008 261005s2024 xx o u000 0 eng d
024 7 _a10.32604/or.2024.050350
_2doi
035 _a(local)EuropePMC:PMC11209743
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aPaulina Chmiel
_eauthor.
245 1 0 _aInflammatory myofibroblastic tumor from molecular diagnostics to current treatment. /
_cPaulina Chmiel; Aleksandra SłOWIKOWSKA; Łukasz Banaszek [and others].
264 1 _a[Place of publication not identified] :
_bTech Science Press,
_c2024.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aInflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aAnaplastic Lymphoma Kinase (Alk)
650 4 _aInflammatory Myofibroblastic Tumor (Imt)
650 4 _aTyrosine Kinase Inhibitors (Tki)
650 4 _aEpithelioid Inflammatory Myofibroblastic Sarcoma
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _amolecular diagnostics
655 4 _aReview articles.
700 0 _aAleksandra SłOWIKOWSKA
_eauthor.
700 0 _aŁukasz Banaszek
_eauthor.
700 0 _aAnna Szumera-CIEćKIEWICZ
_eauthor.
700 0 _aBARTłOMIEJ Szostakowski
_eauthor.
700 0 _aMateusz J SPAłEK
_eauthor.
700 0 _aTomasz Świtaj
_eauthor.
700 0 _aPiotr Rutkowski
_eauthor.
700 0 _aAnna M Czarnecka
_eauthor.
773 0 _tOncology research
_gVol. 32, no. 7, (2024), pages/article 1141-1162
_x0965-0407
856 4 0 _uhttps://europepmc.org/articles/PMC11209743
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC11209743
_qlocal
942 _n0
999 _c1201
_d1201